Polysaccharide Krestin Prevents Alzheimer's Disease-type Pathology and Cognitive Deficits by Enhancing Monocyte Amyloid-β Processing

Neurosci Bull. 2022 Mar;38(3):290-302. doi: 10.1007/s12264-021-00779-5. Epub 2021 Oct 6.

Abstract

Deficits in the clearance of amyloid β protein (Aβ) by the peripheral system play a critical role in the pathogenesis of sporadic Alzheimer's disease (AD). Impaired uptake of Aβ by dysfunctional monocytes is deemed to be one of the major mechanisms underlying deficient peripheral Aβ clearance in AD. In the current study, flow cytometry and biochemical and behavioral techniques were applied to investigate the effects of polysaccharide krestin (PSK) on AD-related pathology in vitro and in vivo. We found that PSK, widely used in therapy for various cancers, has the potential to enhance Aβ uptake and intracellular processing by human monocytes in vitro. After administration of PSK by intraperitoneal injection, APP/PS1 mice performed better in behavioral tests, along with reduced Aβ deposition, neuroinflammation, neuronal loss, and tau hyperphosphorylation. These results suggest that PSK holds promise as a preventive agent for AD by strengthening the Aβ clearance by blood monocytes and alleviating AD-like pathology.

Keywords: Alzheimer’s disease; Aβ uptake; Monocyte; Polysaccharide krestin.

MeSH terms

  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides* / metabolism
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Cognition
  • Disease Models, Animal
  • Mice
  • Mice, Transgenic
  • Monocytes / metabolism
  • Monocytes / pathology
  • Polysaccharides / pharmacology
  • Polysaccharides / therapeutic use
  • Proteoglycans

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Polysaccharides
  • Proteoglycans
  • polysaccharide-K